

## Pertussis

Pertussis, or whooping cough, is an acute infectious disease caused by the bacterium *Bordetella pertussis*. Outbreaks of pertussis were first described in the 16th century, and the organism was first isolated in 1906.

In the 20th century, pertussis was one of the most common childhood diseases and a major cause of childhood mortality in the United States. Before the availability of pertussis vaccine in the 1940s, more than 200,000 cases of pertussis were reported annually. Since widespread use of the vaccine began, incidence has decreased more than 80% compared with the prevaccine era.

Pertussis remains a major health problem among children in developing countries, with 195,000 deaths resulting from the disease in 2008 (World Health Organization estimate).

## *Bordetella pertussis*

*B. pertussis* is a small, aerobic gram-negative rod. It is fastidious and requires special media for isolation (see Laboratory Diagnosis).

*B. pertussis* produces multiple antigenic and biologically active products, including pertussis toxin, filamentous hemagglutinin, agglutinogens, adenylate cyclase, pertactin, and tracheal cytotoxin. These products are responsible for the clinical features of pertussis disease, and an immune response to one or more produces immunity following infection. Immunity following *B. pertussis* infection does not appear to be permanent.

## Pathogenesis

Pertussis is primarily a toxin-mediated disease. The bacteria attach to the cilia of the respiratory epithelial cells, produce toxins that paralyze the cilia, and cause inflammation of the respiratory tract, which interferes with the clearing of pulmonary secretions. Pertussis antigens appear to allow the organism to evade host defenses, in that lymphocytosis is promoted but chemotaxis is impaired. Until recently it was thought that *B. pertussis* did not invade the tissues. However, recent studies have shown the bacteria to be present in alveolar macrophages.

## Clinical Features

The incubation period of pertussis is commonly 7–10 days, with a range of 4–21 days, and rarely may be as long as 42 days. The clinical course of the illness is divided into three stages.

### Pertussis

- Highly contagious respiratory infection caused by *Bordetella pertussis*
- Outbreaks first described in 16th century
- *Bordetella pertussis* isolated in 1906
- Estimated 294,000 deaths worldwide in 2002

### *Bordetella pertussis*

- Fastidious gram-negative bacteria
- Antigenic and biologically active components:
  - pertussis toxin (PT)
  - filamentous hemagglutinin (FHA)
  - agglutinogens
  - adenylate cyclase
  - pertactin
  - tracheal cytotoxin

### Pertussis Pathogenesis

- Primarily a toxin-mediated disease
- Bacteria attach to cilia of respiratory epithelial cells
- Inflammation occurs which interferes with clearance of pulmonary secretions
- Pertussis antigens allow evasion of host defenses (lymphocytosis promoted but impaired chemotaxis)

### Pertussis Clinical Features

- Incubation period 7-10 days (range 4-21 days)
- Insidious onset, similar to minor upper respiratory infection with nonspecific cough
- Fever usually minimal throughout course of illness

# Pertussis

## Pertussis Clinical Features

- Catarrhal stage 1-2 weeks
- Paroxysmal cough stage 1-6 weeks
- Convalescence Weeks to months

## Pertussis Among Adolescents and Adults

- Disease often milder than in infants and children
- Infection may be asymptomatic, or may present as classic pertussis
- Persons with mild disease may transmit the infection
- Older persons often source of infection for children

## Pertussis Complications\*

<u>Condition</u>	<u>Percent reported</u>
Pneumonia	5.2
Seizures	0.8
Encephalopathy	0.1
Hospitalization	20
Death	0.2

\*Cases reported to CDC 1997-2000 (N=28,187)

The first stage, the catarrhal stage, is characterized by the insidious onset of coryza (runny nose), sneezing, low-grade fever, and a mild, occasional cough, similar to the common cold. The cough gradually becomes more severe, and after 1–2 weeks, the second, or paroxysmal stage, begins. Fever is generally minimal throughout the course of the illness.

It is during the paroxysmal stage that the diagnosis of pertussis is usually suspected. Characteristically, the patient has bursts, or paroxysms, of numerous, rapid coughs, apparently due to difficulty expelling thick mucus from the tracheobronchial tree. At the end of the paroxysm, a long inspiratory effort is usually accompanied by a characteristic high-pitched whoop. During such an attack, the patient may become cyanotic (turn blue). Children and young infants, especially, appear very ill and distressed. Vomiting and exhaustion commonly follow the episode. The person does not appear to be ill between attacks.

Paroxysmal attacks occur more frequently at night, with an average of 15 attacks per 24 hours. During the first 1 or 2 weeks of this stage, the attacks increase in frequency, remain at the same level for 2 to 3 weeks, and then gradually decrease. The paroxysmal stage usually lasts 1 to 6 weeks but may persist for up to 10 weeks. Infants younger than 6 months of age may not have the strength to have a whoop, but they do have paroxysms of coughing.

In the convalescent stage, recovery is gradual. The cough becomes less paroxysmal and disappears in 2 to 3 weeks. However, paroxysms often recur with subsequent respiratory infections for many months after the onset of pertussis.

Adolescents and adults and children partially protected by the vaccine may become infected with *B. pertussis* but may have milder disease than infants and young children. Pertussis infection in these persons may be asymptomatic, or present as illness ranging from a mild cough illness to classic pertussis with persistent cough (i.e., lasting more than 7 days). Inspiratory whoop is not common.

Even though the disease may be milder in older persons, those who are infected may transmit the disease to other susceptible persons, including unimmunized or incompletely immunized infants. Older persons are often found to have the first case in a household with multiple pertussis cases, and are often the source of infection for children.

## Complications

The most common complication, and the cause of most pertussis-related deaths, is secondary bacterial pneumonia. Young infants are at highest risk for acquiring pertussis-associated complications. Data from 1997–2000 indicate that

pneumonia occurred in 5.2% of all reported pertussis cases, and among 11.8% of infants younger than 6 months of age.

Neurologic complications such as seizures and encephalopathy (a diffuse disorder of the brain) may occur as a result of hypoxia (reduction of oxygen supply) from coughing, or possibly from toxin. Neurologic complications of pertussis are more common among infants. Other less serious complications of pertussis include otitis media, anorexia, and dehydration. Complications resulting from pressure effects of severe paroxysms include pneumothorax, epistaxis, subdural hematomas, hernias, and rectal prolapse.

In 2004 through 2008 a total of 111 deaths from pertussis were reported to the CDC. Children 3 months of age or younger accounted for 92 (83%) of these deaths.

Adolescents and adults may also develop complications of pertussis, such as difficulty sleeping, urinary incontinence, pneumonia, and rib fracture.


## Laboratory Diagnosis

The diagnosis of pertussis is based on a characteristic clinical history (cough for more than 2 weeks with whoop, paroxysms, or posttussive vomiting) as well as a variety of laboratory tests (culture, polymerase chain reaction [PCR], direct fluorescent antibody [DFA] and serology).

Culture is considered the gold standard laboratory test and is the most specific of the laboratory tests for pertussis. However, fastidious growth requirements make *B. pertussis* difficult to culture. The yield of culture can be affected by specimen collection, transportation, and isolation techniques. Specimens from the posterior nasopharynx, not the throat, should be obtained using Dacron® or calcium alginate (not cotton) swabs. Isolation rates are highest during the first 3 to 4 weeks of illness (catarrhal and early paroxysmal stages). Cultures are variably positive (30%–50%) and may take as long as 2 weeks, so results may be too late for clinical usefulness. Cultures are less likely to be positive if performed later in the course of illness (more than 2 weeks after cough onset) or on specimens from persons who have received antibiotics or have been vaccinated. Since adolescents and adults have often been coughing for several weeks before they seek medical attention, it is often too late for culture to be useful.

Because of the increased sensitivity and faster reporting of results of PCR, many laboratories are now using this method exclusively. PCR should be used in addition to, and not as a replacement for culture. No PCR product has been approved by the Food and Drug Administration (FDA), and there are no standardized protocols, reagents, or reporting

### Pertussis Complications by Age



\*Cases reported to CDC 1997-2000 (N=28,187)

### Pertussis Deaths in the United States, 2004-2008

	Age at onset		Total
	<3 mos	≥3 mos	
2004	23	4	27
2005	32	7	39
2006	12	5	16
2007	9	2	11
2008	16	2	18
Total	92	20	111
	(83%)	(17%)	

CDC, unpublished data, 2009

formats for pertussis PCR testing. Consequently, PCR assays vary widely among laboratories. Specificity can be poor, with high rates of false-positive results in some laboratories. Like culture, PCR is also affected by specimen collection. An inappropriately obtained nasopharyngeal swab will likely be negative by both culture and PCR. PCR is less affected by prior antibiotic therapy, since the organism does not need to be viable to be positive by PCR. Continued use of culture is essential for confirmation of PCR results.

DFA testing of nasopharyngeal specimens may be useful as a rapid screening test for pertussis. Use of the monoclonal DFA test has improved the specificity, but DFA still has a low sensitivity and should not be relied upon as a criterion for laboratory confirmation.

Serologic testing could be useful for adults and adolescents who present late in the course of their illness, when both culture and PCR are likely to be negative. However, there is no FDA-approved diagnostic test. The currently available serologic tests measure antibodies that could result from either infection or vaccination, so a positive serologic response simply means that the person has been exposed to pertussis by either recent or remote infection or by recent or remote vaccination. Since vaccination can induce both IgM and IgA antibodies (in addition to IgG antibodies), use of such serologic assays cannot differentiate infection from vaccine response. At this time, serologic test results should not be relied upon for case confirmation of pertussis infection.

An elevated white blood cell count with a lymphocytosis is usually present in classical disease of infants. The absolute lymphocyte count often reaches 20,000 or greater. However, there may be no lymphocytosis in some infants and children or in persons with mild or modified cases of pertussis. More information on the laboratory diagnosis of pertussis is available at <http://www.cdc.gov/vaccines/pubs/surv-manual/default.pdf>

## Medical Management

The medical management of pertussis cases is primarily supportive, although antibiotics are of some value. Erythromycin is the drug of choice. This therapy eradicates the organism from secretions, thereby decreasing communicability and, if initiated early, may modify the course of the illness.

An antibiotic effective against pertussis (such as azithromycin, erythromycin or trimethoprim-sulfamethoxazole) should be administered to all close contacts of persons with pertussis, regardless of age and vaccination status. Revised treatment and postexposure prophylaxis recommendations were published in December 2005 (see reference list). All

close contacts younger than 7 years of age who have not completed the four-dose primary series should complete the series with the minimal intervals. (see table in Appendix A). Close contacts who are 4–6 years of age and who have not yet received the second booster dose (usually the fifth dose of DTaP) should be vaccinated. The administration of Tdap to persons who have been exposed to a person with pertussis is not contraindicated, but the efficacy of postexposure use of Tdap is unknown.

## Epidemiology

### Occurrence

Pertussis occurs worldwide.

### Reservoir

Pertussis is a human disease. No animal or insect source or vector is known to exist. Adolescents and adults are an important reservoir for *B. pertussis* and are often the source of infection for infants.

### Transmission

Transmission most commonly occurs by the respiratory route through contact with respiratory droplets, or by contact with airborne droplets of respiratory secretions. Transmission occurs less frequently by contact with freshly contaminated articles of an infected person.

### Temporal Pattern

Pertussis has no distinct seasonal pattern, but it may increase in the summer and fall.

### Communicability

Pertussis is highly communicable, as evidenced by secondary attack rates of 80% among susceptible household contacts. Persons with pertussis are most infectious during the catarrhal period and the first 2 weeks after cough onset (i.e., approximately 21 days).

### Secular Trends in the United States


Before the availability of vaccine, pertussis was a common cause of morbidity and mortality among children. During the 6-year period from 1940 through 1945, more than 1 million cases of pertussis were reported, an average of 175,000 cases per year (incidence of approximately 150 cases per 100,000 population).

Following introduction of whole-cell pertussis vaccine in the 1940s, pertussis incidence gradually declined, reaching

### Pertussis Epidemiology


- Reservoir Human  
Adolescents and adults
- Transmission Respiratory droplets
- Communicability Maximum in catarrhal stage  
Secondary attack rate up to 80%

Pertussis—United States, 1940-2009




# Pertussis

**Pertussis—United States, 1980-2009**



**Reported Pertussis by Age Group, 1990-2008**



CDC, unpublished data, 2009

15,000 reported cases in 1960 (approximately 8 per 100,000 population). By 1970, annual incidence was fewer than 5,000 cases per year, and during 1980–1990, an average of 2,900 cases per year were reported (approximately 1 per 100,000 population).

Pertussis incidence has been gradually increasing since the early 1980s. A total of 25,827 cases was reported in 2004, the largest number since 1959. The reasons for the increase are not clear. A total of 27,550 pertussis cases and 27 pertussis-related deaths were reported in 2010.

During 2001–2003, the highest average annual pertussis incidence was among infants younger than 1 year of age (55.2 cases per 100,000 population), and particularly among children younger than 6 months of age (98.2 per 100,000 population). In 2002, 24% of all reported cases were in this age group. However, in recent years, adolescents (11–18 years of age) and adults (19 years and older) have accounted for an increasing proportion of cases. During 2001–2003, the annual incidence of pertussis among persons aged 10–19 years increased from 5.5 per 100,000 in 2001, to 6.7 in 2002, and 10.9 in 2003. In 2004 and 2005, approximately 60% of reported cases were among persons 11 years of age and older. Increased recognition and diagnosis of pertussis in older age groups probably contributed to this increase of reported cases among adolescents and adults.

## Pertussis Surveillance

For information about pertussis surveillance and information about the case definition, and case classification see [www.cdc.gov/vaccines/pubs/surv-manual/default.htm](http://www.cdc.gov/vaccines/pubs/surv-manual/default.htm).

## Pertussis Vaccines

### Whole-Cell Pertussis Vaccine

Whole-cell pertussis vaccine is composed of a suspension of formalin-inactivated *B. pertussis* cells. It was developed in the 1930s and used widely in clinical practice by the mid-1940s.

Based on controlled efficacy trials conducted in the 1940s and on subsequent observational efficacy studies, a primary series of four doses of whole-cell DTP vaccine was 70%–90% effective in preventing serious pertussis disease. Protection decreased with time, resulting in little or no protection 5 to 10 years following the last dose. Local reactions such as redness, swelling, and pain at the injection site occurred following up to half of doses of whole-cell DTP vaccines. Fever and other mild systemic events were also common. Concerns about safety led to the development of more purified (acellular) pertussis vaccines that are associated with a lower frequency of adverse

### Whole-Cell Pertussis Vaccine

- Developed in mid-1930s and combined as DTP in mid-1940s
- 70%–90% efficacy after 3 doses
- Protection for 5–10 years
- Local adverse reactions common

reactions. Whole-cell pertussis vaccines are no longer available in the United States but are still used in many other countries.

## Acellular Pertussis Vaccine

### Characteristics

Acellular pertussis vaccines are subunit vaccines that contain purified, inactivated components of *B. pertussis* cells. Several acellular pertussis vaccines have been developed for different age groups; these contain different pertussis components in varying concentrations. Acellular pertussis vaccines are available only as combinations with tetanus and diphtheria toxoids.

### Pediatric Formulation (DTaP)

Three pediatric acellular pertussis vaccines are currently available for use in the United States. All three vaccines are combined with diphtheria and tetanus toxoids as DTaP and are approved for children 6 weeks through 6 years of age (to age 7 years). *Infanrix* (GlaxoSmithKline) contains three antigens, mostly pertussis toxin (PT) and FHA. *Tripedia* (sanofi pasteur) contains two components, FHA and PT, in equal amounts. *Daptacel* (sanofi pasteur) contains five components, PT, FHA, pertactin, and fimbriae types 2 and 3. None of the available DTaP vaccines contains thimerosal as a preservative, although *Infanrix* and *Daptacel* contain 2-phenoxyethanol as a preservative. *Tripedia* does not contain a preservative. All three vaccines are supplied in single-dose vials or syringes.

### Adolescent and Adult Formulation (Tdap)

Acellular pertussis-containing vaccines were first licensed for adolescents and adults in 2005. Two vaccines are currently available. Both vaccines are combined with tetanus toxoid and a reduced amount of diphtheria toxoid compared with pediatric DTaP (that is, similar quantities of tetanus and diphtheria toxoid to adult formulation Td). *Boostrix* (GlaxoSmithKline) is approved for persons 10 years of age and older, and contains three pertussis antigens (PT, FHA, and pertactin) in a reduced quantity compared with the GlaxoSmithKline pediatric formulation. The vaccine contains aluminum hydroxide as an adjuvant and does not contain a preservative. *Adacel* (sanofi pasteur) is approved for persons 11 through 64 years of age. It contains the same five pertussis components as *Daptacel* but with a reduced quantity of PT. *Adacel* contains aluminum phosphate as an adjuvant and does not contain a preservative. Both vaccines are supplied in single-dose vials or syringes.

### Pertussis-containing Vaccines

- DTaP (pediatric)
  - approved for children 6 weeks through 6 years (to age 7 years)
- Tdap (adolescent and adult)
  - approved for persons 10 through 64 years (*Boostrix*) and 11 through 64 years (*Adacel*)

15

### Composition\* of Acellular Pertussis Vaccines

Product	PT	FHA	PERT	FIM
<i>Daptacel</i>	10	5	3	5
<i>Infanrix</i>	25	25	8	--
<i>Tripedia</i>	23	23	--	--
<i>Boostrix</i>	8	8	2.5	--
<i>Adacel</i>	2.5	5	3	5

\*mcg per dose

## DTaP Clinical Trials

<u>Product</u>	<u>Location</u>	<u>VE (95% CI)</u>
Daptacel	Sweden	85% (80-89)
Tripedia	Germany	80% (59-90)
Infanrix	Italy	84% (76-89)

## Routine DTaP Primary Vaccination Schedule

<u>Dose</u>	<u>Age</u>	<u>Minimum Interval</u>
Primary 1	2 months	---
Primary 2	4 months	4 weeks
Primary 3	6 months	4 weeks
Primary 4	15-18 months	6 months

## Immunogenicity and Vaccine Efficacy

### DTaP

Since 1991, several studies conducted in Europe and Africa have evaluated the efficacy of DTaP vaccines administered to infants. These studies varied in type and number of vaccines, design, case definition, and laboratory method used to confirm the diagnosis of pertussis, so comparison among studies must be made with caution. Point estimates of vaccine efficacy ranged from 80% to 85% for vaccines currently licensed in the United States. Confidence intervals for vaccine efficacy overlap, suggesting that none of the vaccines is significantly more effective than the others. When studied, the acellular pertussis vaccine was significantly more effective than whole-cell DTP. Mild local and systemic adverse reactions and more serious adverse reactions (such as high fever, persistent crying, hypotonic hyporesponsive episodes, and seizures) occurred less frequently among infants vaccinated with acellular pertussis vaccines than among those vaccinated with whole-cell DTP.

### Tdap

Adolescent and adult formulation Tdap vaccines were licensed on the basis of noninferiority of the serologic response to the various components compared with each company's pediatric DTaP formulation (Infanrix and Daptacel) among persons who had received pediatric DTaP or DTP in childhood. For both vaccines, the antibody response to a single dose of Tdap was similar to that following three doses of DTaP in infants. This type of study is known as "bridging." The new vaccines are assumed to have similar clinical efficacy as DTaP vaccine since a similar level of antibody to the components was achieved.

## Vaccination Schedule and Use

### DTaP

The primary series of DTaP vaccine consists of four doses, the first three doses given at 4- to 8-week intervals (minimum of 4 weeks), beginning at 6 weeks to 2 months of age. The fourth dose is given 6–12 months after the third to maintain adequate immunity for the ensuing preschool years. DTaP should be administered simultaneously with all other indicated vaccines.

The fourth dose of all brands of DTaP is licensed, and recommended by ACIP, to be administered at 15–18 months of age (17–20 months for Daptacel). However, ACIP recommends that in certain circumstances the fourth dose be given earlier than 15 months of age. The fourth dose of DTaP may be given if the child is at least 12 months of age, and at least 6 months have elapsed since the third dose



of pertussis vaccine was given, and, in the opinion of the immunization provider, the child is unlikely to return for an additional visit at 15–18 months of age. All three of these criteria should be met in order to administer the fourth dose of DTaP at 12–14 months of age.

Children who received all four primary doses before the fourth birthday should receive a fifth (booster) dose of DTaP before entering school. This booster dose is not necessary (but may be given) if the fourth dose in the primary series was given on or after the fourth birthday. The booster dose increases antibody levels and may decrease the risk of school-age children transmitting the disease to younger siblings who are not fully vaccinated.

ACIP recommends that the series be completed with the same brand of DTaP vaccine if possible. However, limited data suggest that “mix and match” DTaP schedules do not adversely affect safety and immunogenicity. If the vaccine provider does not know or have available the type of DTaP vaccine previously administered to a child, any available DTaP vaccine should be used to continue or complete the vaccination series. Unavailability of the vaccine used for earlier doses is not a reason for missing the opportunity to administer a dose of acellular pertussis vaccine for which the child is eligible.

Interruption of the recommended schedule or delayed doses does not lead to a reduction in the level of immunity reached on completion of the primary series. There is no need to restart a series regardless of the time that has elapsed between doses.

## **Tdap**

Both Tdap vaccines are approved by the Food and Drug Administration for a single (booster) dose for persons who have completed the recommended childhood DTP/DTaP vaccination series. Boostrix is approved for persons 10 years of age and older; Adacel is approved for persons 11 through 64 years of age.

ACIP recommends a single Tdap dose for persons aged 11 through 18 years who have completed the recommended childhood diphtheria and tetanus toxoids and pertussis/diphtheria and tetanus toxoids and acellular pertussis (DTP/DTaP) vaccination series and for adults aged 19 through 64 years.

Children 7 through 10 years of age who are not fully vaccinated against pertussis (defined as having received fewer than 4 doses of DTaP, or having received 4 doses of DTaP but the last dose was prior to age 4 years) and who do not have a contraindication to pertussis vaccine should receive

### **DTaP Fourth Dose**

- Recommended at 15-18 months\*
- May be given earlier if:
  - child is 12 months of age, and
  - 6 months since DTaP3, and
  - unlikely to return at 15-18 months

\*17-20 months for Daptacel

### **Interchangeability of Different Brands of DTaP Vaccine**

- Series should be completed with same brand of vaccine if possible
- Limited data suggest that “mix and match” DTaP schedules do not adversely affect safety and immunogenicity
- Use different brand of DTaP if necessary

### **Tdap Vaccines**

- Boostrix (GlaxoSmithKline)
  - approved for persons 10 years of age and older
- Adacel (sanofi pasteur)
  - approved for persons 11 through 64 years of age

### Tdap Recommendations

- A single dose of Tdap is recommended for
  - adolescents 11-18 years of age (preferably at 11 or 12 years of age)
  - adults 19-64 years of age
  - children 7-10 years of age who are not fully vaccinated against pertussis\*
  - adults 65 years of age and older who have or anticipate having close contact with an infant less than 12 months of age

\*Not fully vaccinated\* against pertussis is defined having received fewer than 4 doses of DTaP, or having received 4 doses of DTaP but the last dose was prior to age 4 years. See MMWR 2011;60(No.1):13-5.

### Tdap Recommendations for Pregnant Women

- Healthcare personnel should implement a Tdap vaccination program for pregnant women who previously have not received Tdap
- Administer Tdap during pregnancy, preferably during the third or late second trimester (after 20 weeks' gestation)
- If not administered during pregnancy, Tdap should be administered immediately postpartum

MMWR 2011;60(No. 41):1424-6

### Tdap Vaccine and Healthcare Personnel

- Healthcare personnel who work in hospitals or ambulatory care settings and have direct patient contact should receive a single dose of Tdap as soon as feasible\*
- Priority should be given to vaccination of healthcare personnel who have direct contact with infants 12 months of age and younger

\*If they have not previously received Tdap.  
MMWR 2006;55(RR-17):1-37

a single dose of Tdap to provide protection against pertussis. If additional doses of tetanus and diphtheria toxoid-containing vaccines are needed, then children 7 through 10 years of age should be vaccinated according to the catch-up schedule, with Tdap preferred as the first dose. Either brand of Tdap may be used. Currently, Tdap is recommended only for a single dose across all age groups. Further guidance will be forthcoming on timing of revaccination in persons who have received Tdap previously.

Adults 65 years of age and older (e.g., grandparents, child care providers, and healthcare practitioners) who have or who anticipate having close contact with an infant younger than 12 months of age and who previously have not received Tdap should receive a single dose of Tdap to protect against pertussis and reduce the likelihood of transmission. For other adults 65 years of age and older, a single dose of Tdap vaccine may be given instead of Td vaccine, in persons who have not previously received Tdap. Either brand of Tdap may be used.

Tdap can be administered regardless of interval since the last tetanus- or diphtheria-toxoid containing vaccine. After receipt of Tdap, persons should continue to receive Td for routine booster immunization against tetanus and diphtheria, generally every 10 years.

ACIP recommends that women's healthcare personnel implement a Tdap vaccination program for pregnant women who previously have not received Tdap. Healthcare personnel should administer Tdap during pregnancy, preferably during the third or late second trimester (after 20 weeks' gestation). If not administered during pregnancy, Tdap should be administered immediately postpartum.

ACIP also recommends that adolescents and adults (e.g., parents, siblings, grandparents, childcare providers, and healthcare personnel) who have or anticipate having close contact with an infant younger than 12 months of age should receive a single dose of Tdap to protect against pertussis if they have not previously received Tdap. Ideally, these persons should receive Tdap at least 2 weeks before beginning close contact with the infant.

Healthcare personnel who work in hospitals or ambulatory care settings and have direct patient contact should receive a single dose of Tdap as soon as feasible. Priority should be given to vaccination of healthcare personnel who have direct contact with infants 12 months of age and younger.

Tdap vaccine may be given at the same visit, or any time before or after any other vaccine.

Immunity following pertussis is not permanent. Persons with a history of pertussis should receive a single dose of Tdap if it is otherwise indicated.

All adolescents and adults should have documentation of having received a primary series of at least three doses of tetanus and diphtheria toxoids during their lifetime. A person without such documentation should receive a series of three doses of tetanus- and diphtheria-containing vaccine. One of these doses, preferably the first, should be Tdap. The remaining two doses should be adult formulation Td.

## Combination Vaccines Containing DTaP

### Pediarix

In 2002, the FDA approved Pediarix (GlaxoSmithKline), the first pentavalent (5 component) combination vaccine licensed in the United States. Pediarix contains DTaP (Infanrix), hepatitis B (Engerix-B), and inactivated polio vaccines.

The minimum age for the first dose of Pediarix is 6 weeks, so it cannot be used for the birth dose of the hepatitis B series. Pediarix is approved for the first three doses of the DTaP and inactivated polio vaccine (IPV) series, which are usually given at about 2, 4, and 6 months of age; it is not approved for fourth or fifth (booster) doses of the DTaP or IPV series. However, Pediarix is approved for use through 6 years of age. A child who is behind schedule can receive Pediarix as long as it is given for doses 1, 2, or 3 of the series, and the child is younger than 7 years of age.

A dose of Pediarix inadvertently administered as the fourth or fifth dose of the DTaP or IPV series does not need to be repeated.

Pediarix may be used interchangeably with other pertussis-containing vaccines if necessary (although ACIP prefers the use of the same brand of DTaP for all doses of the series, if possible). It can be given at 2, 4, and 6 months to infants who received a birth dose of hepatitis B vaccine (total of four doses of hepatitis B vaccine). Although not labeled for this indication by FDA, Pediarix may be used in infants whose mothers are HBsAg positive or whose HBsAg status is not known.

### Pentacel

Pentacel is a combination vaccine that contains lyophilized Hib (ActHIB) vaccine that is reconstituted with a liquid DTaP-IPV solution. The vaccine was licensed by FDA in June

#### Tdap For Persons Without A History of DTP or DTaP

- All adolescents and adults should have documentation of having received a series of DTaP, DTP, DT, or Td
- Persons without documentation should receive a series of 3 vaccinations
- Preferred schedule:
  - single dose of Tdap\*
  - Td at least 4 weeks after the Tdap dose
  - second dose of Td at least 6 months after the Td dose

\*off-label recommendation. *MMWR* 2006;55(RR-3):1-43

#### Pediarix

- DTaP–Hep B–IPV combination
- Minimum age 6 weeks
- Approved for 3 doses at 2, 4 and 6 months
- Not approved for booster doses
- Licensed for children 6 weeks through 6 years of age

#### Pediarix

- May be used interchangeably with other pertussis-containing vaccines if necessary
- Can be given at 2, 4, and 6 months to infants who received a birth dose of hepatitis B vaccine (total of 4 doses)
- May be used in infants whose mothers are HBsAg positive or status is not known\*

\*off-label recommendation

#### Pentacel Vaccine

- Contains lyophilized Hib (ActHIB) vaccine that is reconstituted with a liquid DTaP-IPV solution
- Approved for doses 1 through 4 among children 6 weeks through 4 years of age
- The DTaP-IPV solution should not be used separately (i.e., only use to reconstitute the Hib component)

2008. Pentacel is licensed by FDA for doses 1 through 4 of the DTaP series among children 6 weeks through 4 years of age. The minimum intervals for Pentacel are determined by the DTaP component. The first three doses must be separated by at least 4 weeks. The fourth dose must be separated from the third by at least 6 calendar months, and not administered before 12 months of age. Pentacel should not be used for the fifth dose of the DTaP series, or for children 5 years or older regardless of the number of prior doses of the component vaccines.

The DTaP-IPV solution is licensed only for use as the diluent for the lyophilized Hib component and should not be used separately.

### Kinrix

Kinrix is a combination vaccine that contains DTaP and inactivated poliovirus vaccine (IPV) that is produced by GlaxoSmithKline. It was approved by the FDA in 2008. Kinrix is licensed only for the fifth dose of DTaP and fourth dose of IPV in children 4 through 6 years of age whose previous DTaP vaccine doses have been with Infanrix and/or Pediarix for the first three doses and Infanrix for the fourth dose. However, if Kinrix is administered to children who received another brand of DTaP for prior DTaP doses the Kinrix dose does not need to be repeated.

### Other DTaP Issues

In certain circumstances, vaccination with DTaP vaccine should be delayed until a child with a known or suspected neurologic condition has been evaluated, treatment initiated, and the condition stabilized. These conditions include the presence of an evolving neurologic disorder (e.g., uncontrolled epilepsy, infantile spasms, and progressive encephalopathy), a history of seizures that has not been evaluated, or a neurologic event that occurs between doses of pertussis vaccine.

A family history of seizures or other neurologic diseases, or stable or resolved neurologic conditions (e.g., controlled idiopathic epilepsy, cerebral palsy, developmental delay) are not contraindications to pertussis vaccination.

Reducing the dose of whole-cell DTP or DTaP vaccine or giving the full dose in multiple smaller doses may result in an altered immune response and inadequate protection. Furthermore, there is no evidence that the chance of a significant vaccine reaction is likely to be reduced by this practice. The use of multiple reduced doses that together equal a full immunizing dose, or the use of smaller, divided doses is not endorsed or recommended. Any vaci-

#### Pertussis Vaccine Use in Children with Underlying Neurologic Disorders

<u>Underlying Condition</u>	<u>Recommendation</u>
Prior seizure	Delay and assess*
Suspected neurologic disorder	Delay and assess*
Neurologic event between doses	Delay and assess*
Stable/resolved neurologic condition	Vaccinate

\*vaccinate after treatment initiated and condition stabilized

nation using less than the standard dose should not be counted, and the person should be revaccinated according to age.

Children who have recovered from documented pertussis do not need additional doses of pediatric pertussis vaccine. However, Tdap vaccine is recommended when the child becomes age eligible. Satisfactory documentation includes recovery of *B. pertussis* on culture or typical symptoms and clinical course when these are epidemiologically linked to a culture-confirmed case, as may occur during outbreaks. When such confirmation of diagnosis is lacking, vaccination should be completed because cough illness may be caused by other *Bordetella* species, other bacteria, or certain viruses.

## Contraindications and Precautions to Vaccination

### DTaP

Contraindications to further vaccination with DTaP are a severe allergic reaction (anaphylaxis) to a vaccine component or following prior dose of vaccine, and encephalopathy not due to another identifiable cause occurring within 7 days after vaccination.

Moderate or severe acute illness is a precaution to vaccination. Children with mild illness, such as otitis media or upper respiratory infection, should be vaccinated. Children for whom vaccination is deferred because of moderate or severe acute illness should be vaccinated when their condition improves.

Certain infrequent adverse reactions following DTaP vaccination are considered to be precautions for subsequent doses of pediatric pertussis vaccine. These adverse reactions are a temperature of 105°F (40.5°C) or higher within 48 hours that is not due to another identifiable cause; collapse or shock-like state (hypotonic hyporesponsive episode) within 48 hours; persistent, inconsolable crying lasting 3 hours or longer, occurring within 48 hours; and convulsions with or without fever occurring within 3 days.

There are circumstances (e.g., during a communitywide outbreak of pertussis) in which the benefit of vaccination outweighs the risk, even if one of the four precautionary adverse reactions occurred following a prior dose. In these circumstances, one or more additional doses of pertussis vaccine should be considered. DTaP should be used in these circumstances.

### Pertussis Vaccination of Children Who Have Recovered From Pertussis

- If documented disease, do not need additional doses of pediatric pertussis vaccine\*
- Satisfactory documentation of disease:
  - recovery of *B. pertussis* on culture, or
  - typical symptoms and clinical course when epidemiologically linked to a culture-confirmed case

\*Tdap is recommended when the child is age eligible

### DTaP Contraindications

- Severe allergic reaction to vaccine component or following a prior dose
- Encephalopathy not due to another identifiable cause occurring within 7 days after vaccination

### DTaP Precautions\*

- Moderate or severe acute illness
- Temperature 105°F (40.5°C) or higher within 48 hours with no other identifiable cause
- Collapse or shock-like state (hypotonic hyporesponsive episode) within 48 hours
- Persistent, inconsolable crying lasting 3 hours or longer, occurring within 48 hours
- Convulsions with or without fever occurring within 3 days

\*may consider use in outbreaks

## Tdap Contraindications

- Severe allergic reaction to vaccine component or following a prior dose
- Encephalopathy not due to another identifiable cause occurring within 7 days after vaccination with a pertussis-containing vaccine

## Tdap Precautions

- History of Guillain-Barré syndrome within 6 weeks after a previous dose of tetanus toxoid-containing vaccine
- Progressive neurologic disorder until the condition has stabilized
- History of a severe local reaction (Arthus reaction) following a prior dose of a tetanus and/or diphtheria toxoid-containing vaccine
- Moderate or severe acute illness

## DTaP Adverse Reactions

- Local reactions (pain, redness, swelling) 20%-40%
- Temp of 101°F or higher 3%-5%
- More severe adverse reactions not common
- Local reactions more common following 4th and 5th doses

## Tdap

Tdap is contraindicated for persons with a history of a severe allergic reaction to a vaccine component or following a prior dose of vaccine. Tdap is also contraindicated for persons with a history of encephalopathy not due to another identifiable cause occurring within 7 days after administration of a pertussis-containing vaccine.

Precautions to Tdap include a history of Guillain-Barré syndrome within 6 weeks after a previous dose of tetanus toxoid-containing vaccine and a progressive neurologic disorder (such as uncontrolled epilepsy or progressive encephalopathy) until the condition has stabilized. Persons with a history of a severe local reaction (Arthus reaction) following a prior dose of a tetanus and/or diphtheria toxoid-containing vaccine should generally not receive Tdap or Td vaccination until at least 10 years have elapsed after the last Td-containing vaccine. Moderate or severe acute illness is a precaution to vaccination. Persons for whom vaccination is deferred because of moderate or severe acute illness should be vaccinated when their condition improves.

As noted above, certain conditions following DTaP vaccine, such as temperature of 105°F or higher, collapse or shock-like state, persistent crying, or convulsions with or without fever are a precaution to subsequent doses of DTaP. However, occurrence of one of these adverse reactions following DTaP vaccine in childhood is not a contraindication or precaution to administration of Tdap to an adolescent or adult. A history of extensive limb swelling following DTaP is not a contraindication to Tdap vaccination. A stable neurologic disorder (such as controlled seizures or cerebral palsy), pregnancy, breastfeeding, and immunosuppression are not contraindications or precautions to administration of Tdap.

## Adverse Reactions Following Vaccination

### DTaP

As with all injected vaccines, administration of DTaP may cause local reactions, such as pain, redness, or swelling. Local reactions have been reported in 20%–40% of children after the first three doses. Local reactions appear to be more frequent after the fourth and/or fifth doses. Mild systemic reactions such as drowsiness, fretfulness, and low-grade fever may also occur. Temperature of 101°F or higher is reported in 3%–5% of DTaP recipients. These reactions are self-limited and can be managed with symptomatic treatment with acetaminophen or ibuprofen. Moderate or severe systemic reactions (such as fever [105°F or higher], febrile seizures, persistent crying lasting 3 hours or longer,

and hypotonic hyporesponsive episodes) have been reported after administration of DTaP but occur less frequently than among children who received whole-cell DTP. Rates of these less common reactions vary by symptom and vaccine but generally occur in fewer than 1 in 10,000 doses. See the pertussis chapter in the textbook *Vaccines* (Plotkin and Orenstein, eds., 2008) for a comprehensive review of DTaP adverse event data.

Information on adverse reactions following a full series of DTaP is also limited. Available data suggest a substantial increase in the frequency and magnitude of local reactions after the fourth and fifth doses. For example, swelling at the site of injection occurred in 2% of patients after the first dose of Tripedia, and in 29% following the fourth dose. Increases in the frequency of fever after the fourth dose have also been reported, although the increased frequencies of other systemic reactions (e.g., fretfulness, drowsiness, or decreased appetite) have not been observed. Further details on this issue can be found in a supplemental ACIP statement published in 2000 (*MMWR* 2000;49(No RR-13):1–8).

Swelling involving the entire thigh or upper arm has been reported after booster doses of certain acellular pertussis vaccines. The limb swelling may be accompanied by erythema, pain and fever. Although the swelling may interfere with walking, most children have no limitation of activity. The pathogenesis and frequency of substantial local reactions and limb swelling are not known, but these conditions appear to be self-limited and resolve without sequelae.

ACIP recommends that a fifth dose of DTaP be administered before a child enters school. It is not known whether children who experience entire limb swelling after a fourth dose of DTaP are at increased risk for this reaction after the fifth dose. Because of the importance of this dose in protecting a child during school years, ACIP recommends that a history of extensive swelling after the fourth dose should not be considered a contraindication to receipt of a fifth dose at school entry. Parents should be informed of the increase in reactogenicity that has been reported following the fourth and fifth doses of DTaP.

## Tdap

The safety of Tdap vaccines was evaluated as part of prelicensure studies. The most common adverse reaction following both brands of Tdap vaccine is a local reaction, such as pain (66%), redness (25%) or swelling (21%) at the site of injection. Temperature of 100.4°F or higher was reported by 1.4% of Tdap recipients and 1.1% of Td recipients. Tdap recipients also reported a variety of nonspecific systemic events, such as headache, fatigue and gastrointestinal

### Adverse Reactions Following the 4th and 5th DTaP Dose

- Local adverse reactions and fever increased with 4th and 5th doses of DTaP
- Reports of swelling of entire limb
- Extensive swelling after 4th dose NOT a contraindication to 5th dose

### Tdap Adverse Reactions

- Local reactions (pain, redness, swelling) 21%-66%
- Temp of 100.4°F or higher 1.4%
- Adverse reactions occur at approximately the same rate as Td alone (without acellular pertussis vaccine)

## **Pertussis-Containing Vaccines Storage and Handling**

- Stored at 35°–46°F (2°–8°C) at all times
- Must never be frozen
- Vaccine exposed to freezing temperature must not be administered and should be discarded
- Should not be used after the expiration date printed on the box or label

symptoms. Local reactions, fever, and nonspecific systemic symptoms occurred at approximately the same rate in recipients of Tdap and the comparison group that received Td without acellular pertussis vaccine. No serious adverse events have been attributed to Tdap.

## **Vaccine Storage and Handling**

DTaP, Td and Tdap vaccines should be stored at 35°–46°F (2°–8°C) at all times. The vaccines must never be frozen. Vaccine exposed to freezing temperature must not be administered and should be discarded. DTaP, Td and Tdap should not be used after the expiration date printed on the box or label.

## **Selected References**

American Academy of Pediatrics. Pertussis. In: Pickering L, Baker CJ, Kimberlin D, Long SS, eds *Red Book: 2009 Report of the Committee on Infectious Diseases*. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2009:504–19.

CDC. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1997;46(No. RR-7):1–25.

CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis. 2005 CDC Guidelines. *MMWR* 2005;54(No. RR-14):1–16.

CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2006;55(No. RR-3):1–43.

CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2006;55(No. RR-17):1–33.

CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) Vaccine from the Advisory Committee on Immunization Practices (ACIP), 2011. *MMWR* 2011;60(No.1):13-15.

CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant <12 months of age – Advisory Committee on Immunization Practices (ACIP), 2011.

Cherry JD, The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of *Bordetella pertussis* infection. *Pediatrics* 2005;115:1422–7.



Greenberg DP. Pertussis in adolescents: increasing incidence brings attention to the need for booster immunization of adolescents. *Pediatr Infect Dis J* 2005;24:721–8.

Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. *N Engl J Med* 2005;353:1555–63.

Woo EJ, Burwen DR, Gatumu SNM, et al. Extensive limb swelling after immunization: Reports to the Vaccine Adverse Event Reporting System. *Clin Infect Dis* 2003;37:351–8.

